Clinical and regulatory intelligence for Long COVID with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 1

Relevant assets

ketamine →

Relevant companies

No related entities indexed yet.

Recent signals(2)

ClinicalJuly 31, 2026

Study on IVIG for Neurological Symptoms in Long COVID Patients

A clinical trial is investigating the efficacy of human immunoglobulin (IVIG) in treating neurological symptoms associated with Long COVID.

ClinicalJuly 21, 2026

Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog

A clinical trial is evaluating the efficacy of ketamine in treating Long COVID symptoms, particularly fatigue and cognitive issues.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Infectious Disease →

Long COVID →

Neurology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.